Relmada Therapeutics (RLMD) Shares Outstanding (Diluted Average) (2015 - 2026)

Relmada Therapeutics (RLMD) has 9 years of Shares Outstanding (Diluted Average) data on file, last reported at $86.6 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 184.77% year-over-year to $86.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.6 million (up 184.77% YoY) and the FY2025 annual result came in at $39.5 million, up 30.88% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $86.6 million in Q1 2026 per RLMD's latest filing, from $39.5 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $86.6 million in Q1 2026 and bottomed at $28.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $30.1 million (2024), against an average of $34.1 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Diluted Average) rose 0.11%; it then soared 184.77% in 2026.
• Tracing RLMD's Shares Outstanding (Diluted Average) over 5 years: stood at $29.6 million in 2022, then climbed by 1.59% to $30.1 million in 2023, then gained by 0.21% to $30.2 million in 2024, then surged by 30.88% to $39.5 million in 2025, then soared by 119.35% to $86.6 million in 2026.
• Per Business Quant, the three latest RLMD Shares Outstanding (Diluted Average) figures stand at $86.6 million (Q1 2026), $39.5 million (Q4 2025), and $32.3 million (Q3 2025).

Peer Comparison